Summary
The potential effect of moexipril, a new converting enzyme inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of warfarin has been investigated.
Ten healthy male volunteers received in a randomised crossover fashion a single oral dose of 50 mg warfarin sodium alone and together with the first dose of 6 days of oral treatment with moexipril 15 mg o.d.
Mean oral plasma clearance of (R)-warfarin was 175 ml·h−1 in the absence and 181 ml·h−1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml·h−1 and 249 ml·h−1. Apparent volume of distribution, peak plasma concentration, time to reach peak concentration and area under the plasma concentration-time curve both of (R)- and (S)-warfarin were not significantly affected. Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.
The results suggest that a clinically important interaction between moexipril and warfarin is unlikely to occur in patients treated with both drugs.
References
Banfield CR, Rowland M (1984) Stereospecific fluoresence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine. J Pharm Sci 73: 1392–1396
Benedek IH, King SYP, Powell RJ, Agra AM, Schary WL, Pieniaszek HJ (1992) Effect of Moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 32: 558–563
Grizzle JE (1965) The two-period change-over design and its use in clinical trials. Biometrics 21: 467–480 and Corrigenda in Biometrics 30: 727 (1974)
O'Reilly RA, Trager WF, Rettie AE, Goulart DA (1987) Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 42: 290–294
Rocci ML, Vlasser PH, Distlerath LM, Gregg MH, Wheeler SC, Zing W, Bjornsson TD (1990) Norfloxacin does not alter warfarin's disposition or anticoagulant effect. J Clin Pharmacol 30: 728–732
Toon S, Holt BL, Mullins GP, Bullingham R, Aarons L, Rowland M (1990) Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 30: 743–750
Toon S, Low LK, Gibaldi M, Trager WF, O'Reilly RA, Motley CH, Goulart DA (1986) The warfarin/sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 39: 15–24
Van Hecken A, De Lepeleire I, Verbesselt R, Arnout J, Angehrn J, Youngberg C, De Schepper PJ (1988) Effect of benazepril, a converting enzyme inhibitor, on plasma levels and activity of acenocoumarol and warfarin. Int J Clin Pharm Res 8: 315–320
White WB, Whelton A, Kaihlanen PM (1993) Assessment of the efficacy and pharmacodynamics of moexipril by ambulatory blood pressure monitoring. Am J Hypertens 6, part 2: 102A
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Hecken, A., Verbesselt, R., Depré, M. et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 45, 291–293 (1993). https://doi.org/10.1007/BF00315400
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315400